Related Experiment Video

Updated: Sep 3, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4)

Michael Juchum1, Bent Pfaffenrot1, Philip Klövekorn1

  • 1Department of Pharmaceutical/Medicinal Chemistry, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, DE, Germany.

European Journal of Medicinal Chemistry
|July 22, 2022
PubMed

Insights

Researchers developed novel Vemurafenib-derived α-carboline inhibitors targeting MKK4 for acute liver failure. These compounds show high selectivity for off-targets while maintaining potency, offering a promising therapeutic avenue.

Area of Science:

  • Medicinal Chemistry
  • Hepatology
  • Molecular Pharmacology

Background:

  • Mitogen-activated protein kinase kinase 4 (MKK4) is a key regulator of hepatocyte regeneration and a potential therapeutic target for acute liver failure.
  • Existing MKK4 inhibitors often lack sufficient selectivity, posing challenges for drug development due to sensitivity to molecular modifications.

Purpose of the Study:

  • To investigate a new class of Vemurafenib-derived inhibitors based on an α-carboline scaffold.
  • To evaluate the potency and selectivity of these novel compounds against MKK4 and relevant off-targets.

Main Methods:

  • Design and synthesis of Vemurafenib-derived α-carboline compounds.
  • In vitro assays to assess MKK4 inhibition.
  • Off-target selectivity profiling.

Main Results:

  • A novel α-carboline scaffold was identified for MKK4 inhibition.
  • The new scaffold demonstrated remarkable intrinsic selectivity towards tested off-targets.
  • Potency against MKK4 was maintained across various structural modifications of the α-carboline derivatives.

Conclusions:

  • Vemurafenib-derived α-carbolines represent a promising new class of MKK4 inhibitors.
  • This scaffold offers an improved balance between potency and selectivity for potential acute liver failure treatments.
  • Further development could lead to novel therapeutics promoting liver regeneration or reducing hepatocyte death.
Keywords:
Acute and chronic liver failureLiver regenerationMKK4 inhibitionNAFLDNASHSelectivityVemurafenibα-carboline

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K